Suppr超能文献

原发性抗生素耐药性对枸橼酸铋雷尼替丁与奥美拉唑为基础的一周三联疗法根除幽门螺杆菌疗效的影响——一项随机对照试验

The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.

作者信息

Bago Josip, Halle Zeljka Belosić, Strinić Dean, Kućisec Nastja, Jandrić Dubravka, Bevanda Milenko, Tomić Monika, Bilić Ante

机构信息

Department of Hepatogastroenterology, Internal Medicine, General Hospital Sveti Duh, Zagreb, Croatia.

出版信息

Wien Klin Wochenschr. 2002 Jun 28;114(12):448-53.

Abstract

AIMS

To compare ranitidine bismuth citrate with omeprazole as to their efficacy to eradicate H. pylori in two different treatment schedules both consisting of a combination of either of above with two antibiotics for 1 week, and to relate these treatment results to primary antibiotic resistance.

METHODS

256 H. pylori positive patients with non-ulcer dyspepsia were randomised to one of the following four treatment groups: omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA); omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM). All drugs were given twice daily for one week. The patients were assessed for prevalence of H. pylori by CLO test, histology and culture on gastric biopsy samples obtained during upper gastrointestinal endoscopy before randomisation and 4-6 weeks after completion of therapy. Bacterial sensitivity to clarithromycin, metronidazole and amoxycillin was determined by E-test.

RESULTS

On per-protocol analysis, overall eradication rates were 96% for RBCCA vs. 85% for OCA (p = 0.03), and 95% for RBCCM vs. 79% for OCM (p = 0.01). Amongst the 196 patients (77% of the entire study group) in whom antibiotic sensitivity testing was technically feasible, primary resistance was found in 8% for clarithromycin, in 33% for metronidazole, and in 0% for amoxycillin. Eradication of clarithromycin sensitive/resistant strains was 89%/40% for OCA (p = 0.0042) and 98%/80% for RBCCA (p = 0.0428). When strains were sensitive to both antibiotics, cure rates with OCM/RBCCM were 87%/96% respectively (p = 0.39), for strains resistant to clarithromycin only, eradication was achieved in 82% with OCM vs. 94% with RBCCM (p = 0.2), and in the case of metronidazole resistance in 85% with OCM vs. 94% with RBCCM (p = 0.09).

CONCLUSIONS

Ranitidine bismuth citrate in combination with clarithromycin and either metronidazole or amoxycillin produced higher eradication rates than omeprazole co-administered with the same antibiotics. This appeared especially prominent in the subgroups with clarithromycin resistance without, however, reaching statistical significance. Efficacy of neither eradication regimen was influenced by metronidazole sensitivity to a significant degree.

摘要

目的

比较枸橼酸铋雷尼替丁与奥美拉唑在两种不同治疗方案中根除幽门螺杆菌的疗效,这两种方案均为上述药物之一与两种抗生素联合使用1周,并将这些治疗结果与原发性抗生素耐药性相关联。

方法

256例幽门螺杆菌阳性的非溃疡性消化不良患者被随机分为以下四个治疗组之一:奥美拉唑20毫克+克拉霉素500毫克+阿莫西林1000毫克(OCA);枸橼酸铋雷尼替丁400毫克+克拉霉素500毫克+阿莫西林1000毫克(RBCCA);奥美拉唑20毫克+克拉霉素500毫克+甲硝唑500毫克(OCM);枸橼酸铋雷尼替丁400毫克+克拉霉素500毫克+甲硝唑500毫克(RBCCM)。所有药物均每日服用两次,共一周。在随机分组前及治疗完成后4 - 6周,通过上消化道内镜检查获取胃活检样本,采用CLO试验、组织学和培养法评估患者幽门螺杆菌的感染情况。通过E试验测定细菌对克拉霉素、甲硝唑和阿莫西林的敏感性。

结果

按符合方案分析,RBCCA的总体根除率为96%,而OCA为85%(p = 0.03);RBCCM为95%,而OCM为79%(p = 0.01)。在196例(占整个研究组的77%)抗生素敏感性检测技术上可行的患者中,发现克拉霉素的原发性耐药率为8%,甲硝唑为33%,阿莫西林为0%。OCA对克拉霉素敏感/耐药菌株的根除率分别为89%/40%(p = 0.0042),RBCCA为98%/80%(p = 0.0428)。当菌株对两种抗生素均敏感时,OCM/RBCCM的治愈率分别为87%/96%(p = 0.39);仅对克拉霉素耐药的菌株,OCM的根除率为82%而RBCCM为94%(p = 0.2);对于甲硝唑耐药的情况,OCM为85%而RBCCM为94%(p = 0.09)。

结论

枸橼酸铋雷尼替丁与克拉霉素及甲硝唑或阿莫西林联合使用时,其根除率高于奥美拉唑与相同抗生素联合使用。这在克拉霉素耐药的亚组中尤为明显,不过未达到统计学意义。两种根除方案的疗效在很大程度上均未受甲硝唑敏感性的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验